Cellscreen Of Australia Plans To Take HPV Test Global
This article was originally published in PharmAsia News
Executive SummaryAustralia's Cellscreen Direct plans to market its Tam-Pap test for the human papilloma virus in a global market it deems to be worth $4 billion. The home test for HPV was approved by the Therapeutics Goods Administration last year to join a vaccine and the pap smear test on the Australian market. Cellscreen said that by raising the funds to go global, it expected to raise the current 60 percent rate for screening, attracting some of the many women uncomfortable with the pap smear. The Australian firm already has applied with the U.S. FDA and expects to seek EU approval early next year. (Click here for more
You may also be interested in...
The last year of the run up to the full implementation of the MDR has been characterized by a flurry of new documents and measures, but industry is adamant that medtech is heading for a crisis that will impact industry and patients alike.
The Chinese government's plan to reduce tariffs it imposed on a slew of US exports is expected to have minimal impact on the overall medtech industry. See what Ralph Ives, AdvaMed's executive VP for global strategy, said about it here.